Cerus Corporation (NASDAQ:CERS) Analyst Rating Consensus

Cerus Corporation (NASDAQ:CERS) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 4 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys.

Other Equity analysts have also commented on the company shares. Brokerage firm BTIG Research maintains its rating on Cerus Corporation (NASDAQ:CERS). As per the latest information, the brokerage house raises the price target to $10 per share from a prior target of $8. The shares have been rated Buy. The rating by the firm was issued on April 22, 2016.

Cerus Corporation (NASDAQ:CERS) stock has received a short term price target of $ 9.25 from 4 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $0.96. The higher estimate of target price is $10 , while the lower price target estimate is $8

Cerus Corporation (NASDAQ:CERS) witnessed a decline in the market cap on Tuesday as its shares dropped 1.63% or 0.1 points. After the session commenced at $6.15, the stock reached the higher end at $6.2 while it hit a low of $5.9. With the volume soaring to 1,110,590 shares, the last trade was called at $6.04. The company has a 52-week high of $6.89. The company has a market cap of $614 million and there are 101,710,815 shares in outstanding. The 52-week low of the share price is $4.27.

Shares of Cerus Corporation rose by 1.34% in the last five trading days and 16.15% for the last 4 weeks. Cerus Corporation is up 0.5% in the last 3-month period. Year-to-Date the stock performance stands at -4.43%.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.